The FCGR3A Phe158Val polymorphism is an independent predictive factor for the efficacy of cetuximab in advanced colorectal cancer (ACC): a study of the Dutch Colorectal Cancer Group (DCCG)

被引：0
|
作者：
Pander, Jan
Gelderblom, Hans
Antonini, Ninja
Tol, Jolien
van der Straaten, Tahar
Punt, Cornelis
Guchelaar, Henk-Jan
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2886
引用
收藏
页数：1
相关论文
共 33 条
  • [1] GSTPI ILE105VAL POLYMORPHISM AND IRINOTECAN EFFICACY IN METASTATIC COLORECTAL CANCER (MCRC), A STUDY OF THE DUTCH COLORECTAL CANCER GROUP (DCCG)
    Kweekel, D. M.
    Koopman, M.
    Antonini, N. F.
    Van der Straaten, T.
    Nortier, H.
    Gelderblom, H.
    Punt, C.
    Guchelaar, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 166 - 166
  • [2] RANDOMIZED PHASE III STUDY OF CAPECITABINE, OXALIPLATIN AND BEVACIZUMAB WITH OR WITHOUT CETUXIMAB IN ADVANCED COLORECTAL CANCER (ACC), THE CAIRO2 STUDY OF THE DUTCH COLORECTAL CANCER GROUP (DCCG)
    Tol, J.
    Koopman, M.
    Antonini, N. F.
    Sinnige, H.
    Valster, F. A. A.
    Braun, J. J.
    ten Tije, A. J.
    Mol, L.
    van Krieken, J. H. J. M.
    Punt, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [3] Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
    Punt, C. J.
    Tol, J.
    Rodenburg, C. J.
    Cats, A.
    Creemers, G.
    Schrama, J. G.
    Erdkamp, F. L.
    Vos, A.
    Mol, L.
    Antonini, N. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Resection of the primary tumour as an independent prognostic factor for survival in patients with advanced colorectal cancer. CAIRO study of the Dutch Colorectal Cancer Group (DCCG)
    Koopman, M.
    Antonini, N. F.
    Vreugdenhil, G.
    Loosveld, O. J. L.
    van Bochove, A.
    Sinnige, H. A. M.
    Creemers, G. J. M.
    Tesselaar, M. E. T.
    Mol, L.
    Punt, C. J. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 250
  • [5] Cardiovascular toxicity of capecitabine, irinotecan, and oxaliplatin in patients with advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study (Cairo)
    Koopman, M.
    antonini, N. F.
    mol, L.
    punt, C. J.
    ANNALS OF ONCOLOGY, 2006, 17 : 122 - 122
  • [6] The correlation between ERCC1 expression and outcome of chemotherapy in patients with advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group study (DCCG)
    Koopman, M.
    Venderbosch, S.
    Antonini, N. F.
    van Krieken, J. H.
    Punt, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study
    Punt, C. J.
    Koopman, M.
    Douma, J.
    Wals, J.
    Honkoop, A. H.
    Erdkamp, F. L.
    de Jong, R. S.
    Rodenburg, C. J.
    Mol, L.
    Antonini, N. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Sequential vs. combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study
    Koopman, M.
    Antonini, N. F.
    Douma, J.
    Wals, J.
    Honkoop, A. H.
    Erdkamp, F. L. G.
    de Jong, R. S.
    Rodenburg, C. J.
    Mol, L.
    Punt, C. J. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 239 - 240
  • [9] Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis
    Tol, J.
    Koopman, M.
    Rodenburg, C. J.
    Cats, A.
    Creemers, G. J.
    de Swart, C. A. M.
    Erdkamp, F. L. G.
    Mol, L.
    Antonini, N. F.
    Punt, C. J. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 234 - 235
  • [10] Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
    Pander, Jan
    Gelderblom, Hans
    Antonini, Ninja F.
    Tol, Jolien
    van Krieken, Johan H. J. M.
    van der Straaten, Tahar
    Punt, Cornelis J. A.
    Guchelaar, Henk-Jan
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1829 - 1834
1234